Skip to content

Effect of Silver Nanoparticles Phonophoresis on Diabetic Foot Ulcer Heeling

Effect of Silver Nanoparticles Phonophoresis on Diabetic Foot Ulcer Heeling

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07821996
Enrollment
36
Registered
2026-09-16
Start date
2025-04-05
Completion date
2026-04-20
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcer

Brief summary

This study was conducted to evaluate the effect of silver nanoparticle phonophoresis on accelerating chronic diabetic foot ulcer healing.

Detailed description

Silver nanoparticle phonophoresis enhances anti-inflammatory actions by reducing pro-inflammatory cytokines. The effectiveness of topical nanoparticles is constrained due to rapid inactivation by biological debris, making phonophoresis an optimal delivery method, which uses low-intensity ultrasound to penetrate deeply into tissues, enhancing permeability and accelerating healing. The study aimed to evaluate the effect of silver nanoparticle phonophoresis on improving healing in chronic diabetic foot ulcers.

Interventions

DEVICEActive silver nanoparticle phonophoresis

A nanosilver gel was directly introduced as the primary coupling interface. An ultrasound device was utilized at a low intensity of 0.5 W/cm², for 1 minute of active sonication per 1 cm² of ulcer size, 2 times per week for 3 weeks

DEVICEIsolated low-intensity pulsed ultrasound therapy

Patients received low-intensity pulsed ultrasound therapy utilizing standard, aqua-gel. After application of ultrasound, the wound bed was dried, and the silver nanoparticle gel was topically applied. It was applied for 2 times per week for 3 weeks.

OTHERStandard wound care

It included standard nursing care (daily dressing and debridement if needed)

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Type1 or Type 2 Diabetes Mellitus with chronic foot ulcer. * Clear clinical documentation of superficial infection.

Exclusion criteria

* Deep bone osteomyelitis. * Peripheral gangrene. * Severe local ischemia. * Pregnancy. * Systemic multi-organ failure.

Design outcomes

Primary

MeasureTime frameDescription
Ulcer Surface Area3 weeksIt was calculated using digital planimetry. A calibration marker was positioned adjacent to the border. The camera of a smartphone having the validated IMITO Wound mobile application was maintained at a distance of 20-30 cm to record the photo and extract ulcer surface area.
Ulcer Volume Displacement Evaluation3 weeksIt was evaluated by the sterile fluid-injection method. Sterile saline solution was injected into the ulcer cavity via a calibrated syringe. The volume of saline injected was measured to determine volumetric dimensions.

Countries

Egypt

Contacts

STUDY_DIRECTORDoaa A Aly

Cairo University

STUDY_CHAIREman M Othman, As.professor

Cairo University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026